JP7403733B2 - インフルエンザｈａスプリットワクチンの製造方法 - Google Patents

インフルエンザｈａスプリットワクチンの製造方法 Download PDF

Info

Publication number
JP7403733B2
JP7403733B2 JP2018137952A JP2018137952A JP7403733B2 JP 7403733 B2 JP7403733 B2 JP 7403733B2 JP 2018137952 A JP2018137952 A JP 2018137952A JP 2018137952 A JP2018137952 A JP 2018137952A JP 7403733 B2 JP7403733 B2 JP 7403733B2
Authority
JP
Japan
Prior art keywords
influenza
split vaccine
vaccine
split
lah
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018137952A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019043937A (ja
JP2019043937A5 (enExample
Inventor
宜聖 高橋
悠 安達
学 阿戸
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DIRECTOR-GENERAL NATIONAL INSTITUTE OF INFECTIOUS DISEASES
Original Assignee
DIRECTOR-GENERAL NATIONAL INSTITUTE OF INFECTIOUS DISEASES
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DIRECTOR-GENERAL NATIONAL INSTITUTE OF INFECTIOUS DISEASES filed Critical DIRECTOR-GENERAL NATIONAL INSTITUTE OF INFECTIOUS DISEASES
Priority to MYPI2020001089A priority Critical patent/MY204177A/en
Priority to SG11202001937TA priority patent/SG11202001937TA/en
Priority to PCT/JP2018/032537 priority patent/WO2019045090A1/ja
Priority to EA202090587A priority patent/EA202090587A1/ru
Priority to KR1020207009033A priority patent/KR102733152B1/ko
Priority to CA3074581A priority patent/CA3074581A1/en
Priority to CN201880070955.0A priority patent/CN111372605B/zh
Priority to EP18852584.4A priority patent/EP3679948A4/en
Priority to AU2018325899A priority patent/AU2018325899B2/en
Priority to US16/292,065 priority patent/US11732031B2/en
Publication of JP2019043937A publication Critical patent/JP2019043937A/ja
Priority to PH12020500414A priority patent/PH12020500414A1/en
Publication of JP2019043937A5 publication Critical patent/JP2019043937A5/ja
Priority to US18/341,960 priority patent/US20230406910A1/en
Application granted granted Critical
Publication of JP7403733B2 publication Critical patent/JP7403733B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/11—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2018137952A 2017-09-04 2018-07-23 インフルエンザｈａスプリットワクチンの製造方法 Active JP7403733B2 (ja)

Priority Applications (12)

Application Number Priority Date Filing Date Title
AU2018325899A AU2018325899B2 (en) 2017-09-04 2018-09-03 Method for producing influenza HA split vaccine
PCT/JP2018/032537 WO2019045090A1 (ja) 2017-09-04 2018-09-03 インフルエンザｈａスプリットワクチンの製造方法
EA202090587A EA202090587A1 (ru) 2017-09-04 2018-09-03 Способ получения сплит-вакцины с на гриппа
KR1020207009033A KR102733152B1 (ko) 2017-09-04 2018-09-03 인플루엔자 ha 스플릿 백신의 제조 방법
CA3074581A CA3074581A1 (en) 2017-09-04 2018-09-03 Method for producing influenza ha split vaccine
CN201880070955.0A CN111372605B (zh) 2017-09-04 2018-09-03 用于产生流感ha裂解疫苗的方法
MYPI2020001089A MY204177A (en) 2017-09-04 2018-09-03 Method for producing influenza ha split vaccine
SG11202001937TA SG11202001937TA (en) 2017-09-04 2018-09-03 Method for producing influenza ha split vaccine
EP18852584.4A EP3679948A4 (en) 2017-09-04 2018-09-03 METHOD OF MANUFACTURING INFLUENZA-HA-SPLIT VACCINE
US16/292,065 US11732031B2 (en) 2017-09-04 2019-03-04 Method for producing influenza HA split vaccine
PH12020500414A PH12020500414A1 (en) 2017-09-04 2020-03-02 Method for producing influenza ha split vaccine
US18/341,960 US20230406910A1 (en) 2017-09-04 2023-06-27 Method for producing influenza ha split vaccine

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2017169230 2017-09-04
JP2017169230 2017-09-04

Publications (3)

Publication Number Publication Date
JP2019043937A JP2019043937A (ja) 2019-03-22
JP2019043937A5 JP2019043937A5 (enExample) 2021-09-02
JP7403733B2 true JP7403733B2 (ja) 2023-12-25

Family

ID=65815411

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018137952A Active JP7403733B2 (ja) 2017-09-04 2018-07-23 インフルエンザｈａスプリットワクチンの製造方法

Country Status (10)

Country Link
US (1) US11732031B2 (enExample)
EP (1) EP3679948A4 (enExample)
JP (1) JP7403733B2 (enExample)
KR (1) KR102733152B1 (enExample)
CN (1) CN111372605B (enExample)
AU (1) AU2018325899B2 (enExample)
CA (1) CA3074581A1 (enExample)
EA (1) EA202090587A1 (enExample)
PH (1) PH12020500414A1 (enExample)
SG (1) SG11202001937TA (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7403733B2 (ja) 2017-09-04 2023-12-25 国立感染症研究所長 インフルエンザｈａスプリットワクチンの製造方法
TW202011986A (zh) 2018-07-23 2020-04-01 公益財團法人日本健康科學振興財團 包含流感疫苗之組合物
PH12021552094A1 (en) 2019-03-04 2022-05-30 Japan As Represented By Director General Of Nat Institute Of Infectious Diseases Method for preparing influenza ha split vaccine
CN114929270A (zh) * 2019-11-07 2022-08-19 塞其里斯英国有限公司 用于生产具有减小的颗粒大小的病毒疫苗的组合物和方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013173256A2 (en) 2012-05-16 2013-11-21 Kj Biosciences, Llc New and improved influenza vaccines
JP2014513680A (ja) 2011-04-21 2014-06-05 バクスター・インターナショナル・インコーポレイテッド ワクチンから抗原を単離し定量する方法
WO2016028776A1 (en) 2014-08-18 2016-02-25 Sanofi Pasteur Biologics Llc Alkylated influenza vaccines

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8278083B2 (en) 2004-03-22 2012-10-02 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Inactivated influenza virus compositions
JPWO2008114819A1 (ja) 2007-03-20 2010-07-08 大日本住友製薬株式会社 新規アデニン化合物
KR20110049802A (ko) 2008-07-25 2011-05-12 인스티튜트 포 리서치 인 바이오메드슨 중화 항-인플루엔자 ａ 바이러스 항체 및 이의 용도
WO2010047509A2 (ko) 2008-10-24 2010-04-29 아주대학교 산학협력단 친화도와 안정성이 향상된 항 ｄｒ5 항체, 및 이를 포함하는 암 예방 또는 치료용 조성물
CN101524538A (zh) * 2009-03-26 2009-09-09 成都康华生物制品有限公司 一种流感-大流行流感二价联合疫苗及其制备方法
JP5795340B2 (ja) 2010-03-08 2015-10-14 セルトリオン インクＣｅｌｌｔｒｉｏｎ，Ｉｎｃ． インフルエンザａ型ウイルスに対して中和活性を有するヒトｂ細胞由来のヒトモノクローナル抗体
JP2013526849A (ja) 2010-03-30 2013-06-27 モウント シナイ スクール オフ メディシネ インフルエンザウイルスワクチン及びその使用
KR20140118682A (ko) 2013-03-29 2014-10-08 (주)셀트리온 2 이상의 인플루엔자 ａ 바이러스 중화 결합 분자를 포함하는 조성물
KR102713707B1 (ko) 2014-12-31 2024-10-04 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 신규 다가 나노입자 기반 백신
JP7403733B2 (ja) 2017-09-04 2023-12-25 国立感染症研究所長 インフルエンザｈａスプリットワクチンの製造方法
TW202011986A (zh) 2018-07-23 2020-04-01 公益財團法人日本健康科學振興財團 包含流感疫苗之組合物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014513680A (ja) 2011-04-21 2014-06-05 バクスター・インターナショナル・インコーポレイテッド ワクチンから抗原を単離し定量する方法
WO2013173256A2 (en) 2012-05-16 2013-11-21 Kj Biosciences, Llc New and improved influenza vaccines
WO2016028776A1 (en) 2014-08-18 2016-02-25 Sanofi Pasteur Biologics Llc Alkylated influenza vaccines

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BYRD L.L. et al.，Journal of Virology，2015年04月，vol.89, no.8，p.4504-4516
Curr. Opin. Immunol. (2016) vol.42, p.83-90
DOMS R.W. et al.，Journal of Virology，1986年12月，vol.60, no.3，p.833-839
長倉三郎ほか編, 岩波 理化学辞典 第５版, 2003年11月, 株式会社 岩波書店, p.327

Also Published As

Publication number Publication date
AU2018325899B2 (en) 2023-04-20
CA3074581A1 (en) 2019-03-07
EP3679948A1 (en) 2020-07-15
EA202090587A1 (ru) 2020-08-24
CN111372605A (zh) 2020-07-03
CN111372605B (zh) 2024-12-17
AU2018325899A1 (en) 2020-04-09
KR102733152B1 (ko) 2024-11-21
JP2019043937A (ja) 2019-03-22
EP3679948A4 (en) 2021-04-28
PH12020500414A1 (en) 2021-03-08
US20190345231A1 (en) 2019-11-14
SG11202001937TA (en) 2020-04-29
KR20200047629A (ko) 2020-05-07
US11732031B2 (en) 2023-08-22

Similar Documents

Publication Publication Date Title
Deng et al. Double-layered protein nanoparticles induce broad protection against divergent influenza A viruses
Kim et al. Multiple heterologous M2 extracellular domains presented on virus-like particles confer broader and stronger M2 immunity than live influenza A virus infection
KR101665141B1 (ko) 인플루엔자 항원 수송 벡터 및 구조물
JP7403733B2 (ja) インフルエンザｈａスプリットワクチンの製造方法
Ben-Yedidia et al. Towards an epitope-based human vaccine for influenza
AU2017321883A1 (en) Stabilized group 2 influenza hemagglutinin stem region trimers and uses thereof
JP7762643B2 (ja) 免疫原性組成物
Du et al. Flu universal vaccines: new tricks on an old virus
JP7545955B2 (ja) インフルエンザｈａスプリットワクチンの製造方法
JP7382634B2 (ja) 交差免疫抗原ワクチン及びその調製方法
CN102153654B (zh) 以免疫活性肽为载体的分支多肽及其衍生物与应用
US20230406910A1 (en) Method for producing influenza ha split vaccine
TWI857017B (zh) 流感ha裂解疫苗之製造方法
Mardanova et al. High immunogenicity of plant-produced influenza based on the M2e peptide fused to flagellin
HK40032891A (en) Method for producing influenza ha split vaccine
EA045852B1 (ru) Способ получения сплит-вакцины с ha гриппа
EA045912B1 (ru) Способ приготовления сплит-вакцины на основе гемагглютинина гриппа
HK40068192A (en) Method for preparing influenza ha split vaccine
JP2024545833A (ja) コロナウイルス科ウイルスによる感染症の処置または予防のためのウイルス様粒子

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180806

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20180827

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20200430

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20200511

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20200430

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20201125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20201125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210719

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210719

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220809

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221006

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221206

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230221

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230421

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230621

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230816

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230912

R150 Certificate of patent or registration of utility model

Ref document number: 7403733

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S631 Written request for registration of reclamation of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R314631

S633 Written request for registration of reclamation of name

Free format text: JAPANESE INTERMEDIATE CODE: R314633

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313111